There's No Pill for a Cocaine Craving. A $20 Gift Card Might Be the Closest Thing We Have.

Someone hands you a $20 gift card for peeing in a cup and testing negative. It feels like a joke, or like you’re being treated as a child who needs a sticker chart. That flinch is the whole story of why cocaine and methamphetamine use disorder are, in 2026, still the only major addictions with zero FDA-approved medications. Ask a doctor for something to blunt a stimulant craving and the honest answer is: there isn’t a pill with your name on it.

There is no medication for stimulant craving — but there is a treatment that beats every drug ever tested against it, and it’s a gift card.

Here’s the plain version before the jargon: craving cocaine or meth isn’t a character flaw you can out-willpower. It’s your brain’s dopamine reward circuit — the system that normally rewards you for eating, connecting, surviving — doing exactly what stimulants trained it to do, firing hardest for the drug and going quiet for everything else, including your own reasons to quit. That’s not a moral failure. It’s biology working against you at the exact moment you need it most.

Contingency management (CM) — get tested, test negative, get paid, right now — works with that circuit instead of fighting it. A small, guaranteed, immediate reward for the behavior you’re trying to build arrives faster than the craving does, which is precisely why it works when lectures and consequences haven’t. The ASAM/AAAP’s 2024 clinical practice guideline named CM the standard of care for stimulant use disorder — ahead of anything in a pharmacy. Weeks later, SAMHSA raised its federal cap on how much grant-funded CM programs can pay a person, from $75 a year to $750 — a tenfold jump. “Given the severity of the addiction crisis and the strong scientific foundation for Contingency Management, this is an important change,” Addiction Policy Forum’s Jessica Hulsey said at the time. As the APA Monitor detailed this spring, that money is now moving through real state Medicaid and Opioid Response-funded programs — not sitting in a research paper.

Medicine isn’t standing still, it’s just behind. Researchers are testing dextroamphetamine and modafinil, controlled stimulants meant to refill the dopamine tank the drug hollowed out, and topiramate, which targets a different craving pathway. None is FDA-approved for this. And a June 2026 JAMA Psychiatry meta-analysis of 12 trials and roughly 2,000 people made an overdue point: when abstinence was the only bar, just 13.3% of people cleared it and nearly every medication looked like a failure. But 31.2% of people achieved a meaningful reduction in use — and one drug, cabergoline, separated from placebo on that measure alone. Demanding perfect abstinence as the only win was hiding treatments that were actually helping.

None of this is guaranteed at your door. The $750 ceiling applies to federal grant dollars — whether a program near you pays it depends on whether your state actually built a contingency management track into its Medicaid or opioid-response funding. Ask your case manager point-blank if one exists.

“No FDA-approved medication” is a true sentence and a misleading one — it describes the pharmacy shelf, not the treatment room. If you’re in recovery from stimulant use, the thing that’s actually shown to work isn’t waiting on the FDA. It’s boring, cheap, dignified, and increasingly funded: show up, get tested, get paid, keep coming back. That’s not a consolation prize. That’s the frontline.